Search research articles
Contact Us
Filters
Showing results (171-180 of 212) with videos related to
Page
of 22
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 13, 2021
Lenalidomide-Epoetin Alfa Versus Lenalidomide Monotherapy in Myelodysplastic Syndromes Refractory to Recombinant Erythropoietin
Alan F List, Zhuoxin Sun, Amit Verma, et al.
The Lancet. Oncology
|
December 9, 2016
Clonal haemopoiesis and therapy-related myeloid malignancies in elderly patients: a proof-of-concept, case-control study
Nancy K Gillis, Markus Ball, Qing Zhang, et al.
Journal of Hematology & Oncology
|
June 28, 2017
Clinical characteristics and outcomes according to age in lenalidomide-treated patients with RBC transfusion-dependent lower-risk MDS and del(5q)
Pierre Fenaux, Aristoteles Giagounidis, Dominik Selleslag, et al.
Cancer
|
November 21, 2014
Outcome of patients with low-risk and intermediate-1-risk myelodysplastic syndrome after hypomethylating agent failure: a report on behalf of the MDS Clinical Research Consortium
Elias J Jabbour, Guillermo Garcia-Manero, Paolo Strati, et al.
Blood
|
April 16, 2020
Phase 1 study of lenzilumab, a recombinant anti-human GM-CSF antibody, for chronic myelomonocytic leukemia
Mrinal M Patnaik, David A Sallman, Abhishek A Mangaonkar, et al.
Biopreservation and Biobanking
|
November 28, 2017
Impact of Specimen Heterogeneity on Biomarkers in Repository Samples from Patients with Acute Myeloid Leukemia: A SWOG Report
Era L Pogosova-Agadjanyan, Anna Moseley, Megan Othus, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 26, 2015
Prognostic significance of NPM1 mutations in the absence of FLT3-internal tandem duplication in older patients with acute myeloid leukemia: a SWOG and UK National Cancer Research Institute/Medical Research Council report
Fabiana Ostronoff, Megan Othus, Michelle Lazenby, et al.
Blood Advances
|
April 23, 2021
Oxidized mitochondrial DNA released after inflammasome activation is a disease biomarker for myelodysplastic syndromes
Grace A Ward, Kathy L McGraw, Farnoosh Abbas-Aghababazadeh, et al.
Oncotarget
|
December 30, 2016
Recurrent genetic defects on chromosome 5q in myeloid neoplasms
Naoko Hosono, Hideki Makishima, Reda Mahfouz, et al.
Haematologica
|
July 16, 2016
Mutational correlates of response to hypomethylating agent therapy in acute myeloid leukemia
Catherine C Coombs, David A Sallman, Sean M Devlin, et al.
Page
of 22
Search research articles
Search
Showing results (171-180 of 212) with videos related to
Sort By:
Page
of 22
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 13, 2021
Lenalidomide-Epoetin Alfa Versus Lenalidomide Monotherapy in Myelodysplastic Syndromes Refractory to Recombinant Erythropoietin
Alan F List, Zhuoxin Sun, Amit Verma, et al.
The Lancet. Oncology
|
December 9, 2016
Clonal haemopoiesis and therapy-related myeloid malignancies in elderly patients: a proof-of-concept, case-control study
Nancy K Gillis, Markus Ball, Qing Zhang, et al.
Journal of Hematology & Oncology
|
June 28, 2017
Clinical characteristics and outcomes according to age in lenalidomide-treated patients with RBC transfusion-dependent lower-risk MDS and del(5q)
Pierre Fenaux, Aristoteles Giagounidis, Dominik Selleslag, et al.
Cancer
|
November 21, 2014
Outcome of patients with low-risk and intermediate-1-risk myelodysplastic syndrome after hypomethylating agent failure: a report on behalf of the MDS Clinical Research Consortium
Elias J Jabbour, Guillermo Garcia-Manero, Paolo Strati, et al.
Blood
|
April 16, 2020
Phase 1 study of lenzilumab, a recombinant anti-human GM-CSF antibody, for chronic myelomonocytic leukemia
Mrinal M Patnaik, David A Sallman, Abhishek A Mangaonkar, et al.
Biopreservation and Biobanking
|
November 28, 2017
Impact of Specimen Heterogeneity on Biomarkers in Repository Samples from Patients with Acute Myeloid Leukemia: A SWOG Report
Era L Pogosova-Agadjanyan, Anna Moseley, Megan Othus, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 26, 2015
Prognostic significance of NPM1 mutations in the absence of FLT3-internal tandem duplication in older patients with acute myeloid leukemia: a SWOG and UK National Cancer Research Institute/Medical Research Council report
Fabiana Ostronoff, Megan Othus, Michelle Lazenby, et al.
Blood Advances
|
April 23, 2021
Oxidized mitochondrial DNA released after inflammasome activation is a disease biomarker for myelodysplastic syndromes
Grace A Ward, Kathy L McGraw, Farnoosh Abbas-Aghababazadeh, et al.
Oncotarget
|
December 30, 2016
Recurrent genetic defects on chromosome 5q in myeloid neoplasms
Naoko Hosono, Hideki Makishima, Reda Mahfouz, et al.
Haematologica
|
July 16, 2016
Mutational correlates of response to hypomethylating agent therapy in acute myeloid leukemia
Catherine C Coombs, David A Sallman, Sean M Devlin, et al.
Page
of 22